Mycosis fungoides secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Mycosis fungoides}} | {{Mycosis fungoides}} | ||
{{CMG}} | {{CMG}} {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
There are no established measures for the secondary prevention of mycosis fungoides. | There are no established measures for the secondary [[Prevention (medical)|prevention]] of mycosis fungoides. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
There are no established measures for the secondary prevention of mycosis fungoides | *There are no established measures for the secondary [[Prevention (medical)|prevention]] of mycosis fungoides. | ||
*Effective measures for the secondary prevention of mycosis fungoides include:<ref name="pmid4438970">{{cite journal |vauthors=Santos JL |title=[Projection of the Brazilian population: 1970-2000] |language=Portuguese |journal=Rev Saude Publica |volume=Suppl |issue= |pages=91–102 |date=June 1974 |pmid=4438970 |doi= |url=}}</ref><ref name="WillemzeHodak2018">{{cite journal|last1=Willemze|first1=R|last2=Hodak|first2=E|last3=Zinzani|first3=P L|last4=Specht|first4=L|last5=Ladetto|first5=M|title=Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†|journal=Annals of Oncology|volume=29|issue=Supplement_4|year=2018|pages=iv30–iv40|issn=0923-7534|doi=10.1093/annonc/mdy133}}</ref> | |||
**Effective measures for the secondary prevention of mycosis fungoides is follow up [[Patient|patients]] with active or progressive [[disease]], every 4–6 weeks. | |||
**[[Light therapy|Phototherapy]] ([[PUVA therapy|PUVA]] and involves oral 8-methoxypsoralen) is the preservation in the early stage. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 04:04, 11 February 2019
|
Mycosis fungoides Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mycosis fungoides secondary prevention On the Web |
|
American Roentgen Ray Society Images of Mycosis fungoides secondary prevention |
|
Risk calculators and risk factors for Mycosis fungoides secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There are no established measures for the secondary prevention of mycosis fungoides.
Secondary Prevention
- There are no established measures for the secondary prevention of mycosis fungoides.
- Effective measures for the secondary prevention of mycosis fungoides include:[1][2]
- Effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
- Phototherapy (PUVA and involves oral 8-methoxypsoralen) is the preservation in the early stage.
References
- ↑ Santos JL (June 1974). "[Projection of the Brazilian population: 1970-2000]". Rev Saude Publica (in Portuguese). Suppl: 91–102. PMID 4438970.
- ↑ Willemze, R; Hodak, E; Zinzani, P L; Specht, L; Ladetto, M (2018). "Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†". Annals of Oncology. 29 (Supplement_4): iv30–iv40. doi:10.1093/annonc/mdy133. ISSN 0923-7534.